The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
SPG601, an oral treatment for fragile X syndrome that's now in clinical testing, has been granted orphan drug status in the European Union.| Fragile X News Today
The FDA has granted orphan drug and rare pediatric disease designations to fragile X treatment KER-0193, Kaerus Biosciences said.| Fragile X News Today
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Investigational therapy BPN14770 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of fragile X syndrome.| Fragile X News Today
